Transmission of HIV drug resistance: lessons from sensitive screening assays
暂无分享,去创建一个
[1] J. Mullins,et al. Lack of Resistance to Integrase Inhibitors among Antiretroviral-Naive Subjects with Primary HIV-1 Infection, 2007–2013 , 2015, Antiviral therapy.
[2] Karin J. Metzner,et al. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing , 2014, The Journal of antimicrobial chemotherapy.
[3] M. Kozal,et al. Deep sequencing of HIV: clinical and research applications. , 2014, Annual review of genomics and human genetics.
[4] M. Kozal,et al. Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects , 2014, Viruses.
[5] H. Stellbrink,et al. Estimating Trends in the Proportion of Transmitted and Acquired HIV Drug Resistance in a Long Term Observational Cohort in Germany , 2014, PloS one.
[6] R. Paredes,et al. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Michael S. Braverman,et al. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. , 2014, Journal of virological methods.
[8] M. Kozal,et al. Prevalence of WHO Transmitted Drug Resistance Mutations by Deep Sequencing in Antiretroviral-Naïve Subjects in Hunan Province, China , 2014, PloS one.
[9] M. Poljak,et al. Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group , 2014, PloS one.
[10] A. Geretti,et al. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. , 2014, The Journal of antimicrobial chemotherapy.
[11] Jonathan Z. Li. HIV-1 drug-resistant minority variants: sweating the small stuff. , 2014, The Journal of infectious diseases.
[12] M. Hughes,et al. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP. , 2014, The Journal of infectious diseases.
[13] David L. Robertson,et al. Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism , 2014, Antimicrobial Agents and Chemotherapy.
[14] H. Günthard,et al. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] T. Thomas,et al. Deep sequencing of evolving pathogen populations: applications, errors, and bioinformatic solutions , 2014, Microbial Informatics and Experimentation.
[16] V. Calvez,et al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. , 2013, The Journal of antimicrobial chemotherapy.
[17] C. Sabin,et al. The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults , 2013, AIDS.
[18] D. Webster,et al. Persistence of HIV-1 Transmitted Drug Resistance Mutations , 2013, The Journal of infectious diseases.
[19] Yongqiang Yang,et al. Advances in nanopore sequencing technology. , 2013, Journal of nanoscience and nanotechnology.
[20] G. Van Domselaar,et al. Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients , 2013, PloS one.
[21] D. Pillay,et al. Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study , 2012, BMJ : British Medical Journal.
[22] P. Kaleebu,et al. Transmitted antiretroviral drug resistance among drug-naive female sex workers with recent infection in Kampala, Uganda. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] F. Wit,et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. , 2012, The Lancet. Infectious diseases.
[24] M. Kozal,et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure , 2012, AIDS.
[25] C. Sabin,et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011 , 2012, HIV medicine.
[26] Cassandra B. Jabara,et al. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID , 2011, Proceedings of the National Academy of Sciences.
[27] David Dunn,et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.
[28] T. F. Rinke de Wit,et al. Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala , 2011, AIDS.
[29] K. Metzner,et al. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure , 2011 .
[30] K. Borroto-Esoda,et al. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy , 2011, AIDS.
[31] D. Richman,et al. Minority variants of drug-resistant HIV. , 2010, The Journal of infectious diseases.
[32] A. Geretti,et al. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. , 2010, The Journal of antimicrobial chemotherapy.
[33] Marco Mancini,et al. Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study , 2010, PloS one.
[34] Anne-Mieke Vandamme,et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.
[35] Gregory S Turenchalk,et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.
[36] R. Paredes,et al. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. , 2007, Journal of virological methods.
[37] S. Barton,et al. Moving forward to meet new challenges , 2000, HIV medicine.
[38] D. Katzenstein,et al. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. , 1993, The Journal of infectious diseases.